Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Bernstein Upgrades Biogen (BIIB) to Outperform
July 27, 2015 8:27 AM EDTBernstein upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $385.00 (from $436.00).
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $300.03 yesterday.
... MoreBaird Downgrades Biogen (BIIB) to Neutral; Diminished Growth Prospects
July 27, 2015 6:35 AM EDTBaird downgraded Biogen (NASDAQ: BIIB) from Outperform to Neutral with a price target of $316.00 (from $480.00), saying lackluster sales and lowered guidance leaves a growth void.
Analyst Brian Skorney commented, "We're aware that this downgrade may be too little, too late given... More
Biogen's (BIIB) Decline Seen as 'Overreaction' at Deutsche Bank
July 24, 2015 3:36 PM EDTDeutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $460. Shares declined after Biogen reported Q2 results and cut full-year guidance. In the view of analyst Robyn Karnauskas, the decline was an "overreaction," though she agrees with sentiment.
"The disappointing run of BIIB continued in Q215 as the co substantially revised 2015 FY guidance due to weaker outlook for Tecfidera.... More
Stocks Hit Session Lows; Biotech, Homebuilders Lead Slump
July 24, 2015 1:33 PM EDTStocks hit session lows Friday afternoon, with the S&P down 0.75% and the Nasdaq lower by 0.5% -- despite huge gains in Amazon.com (NASDAQ: AMZN).
Biotech was among the worst performing sectors with ETFs like iShares Nasdaq Biotechnology (NASDAQ:... More
Biogen (BIIB) Trading at 'Pharma-Like' Multiple, Cowen Says
July 24, 2015 1:04 PM EDTCowen analyst Eric Schmidt reiterated his Outperform rating and $494 price target on Biogen (NASDAQ: BIIB), with shares down nearly 20% on disappointing Q2 results and outlook. Schmidt maintained his bullish view, saying the stock is trading at a 'pharma-like' multiple.
Schmidt commented,... More
Biogen (BIIB) Worth a 'Hard Look' when Smoke Clears, Stifel Says
July 24, 2015 12:19 PM EDTStifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) following disappointing Q2 results, which has shares down 18.4% intra-day. While retaining his Hold rating, the analyst said the stock is worth a hard look when the smoke clears.
Shrader commented, "Biogens numbers were... More
